leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


12345678910111213...235236»
  • ||||||||||  methotrexate / Generic mfg.
    Methotrexate and Kidney Function: Differential Effects of High versus Low-Dose () -  Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_693;    
    The patient was continued on isotonic bicarbonate, leucovorin, and received glucarpidase...In contrast, LD-MTX has not definitively been associated with kidney dysfunction. In patients taking LD-MTX, considerations of alternative etiologies for declines in eGFR should be explored.Conclusion When evaluating acute kidney injury in patients who are taking methotrexate, medication dose and associated risk for nephrotoxicity must be considered.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS
    Trial completion, Trial completion date, Trial primary completion date, Tumor mutational burden:  NIVACOR: Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (clinicaltrials.gov) -  Mar 13, 2025   
    P2,  N=73, Completed, 
    In patients taking LD-MTX, considerations of alternative etiologies for declines in eGFR should be explored.Conclusion When evaluating acute kidney injury in patients who are taking methotrexate, medication dose and associated risk for nephrotoxicity must be considered. Unknown status --> Completed | Trial completion date: Sep 2022 --> Oct 2024 | Trial primary completion date: Sep 2022 --> Aug 2024
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Tukysa (tucatinib) / Pfizer, Perjeta (pertuzumab) / Roche
    Review, Journal:  HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers. (Pubmed Central) -  Mar 12, 2025   
    This review aims to summarize the rapidly evolving landscape of HER2-directed agents for BTCs, highlighting current evidence of survival benefit. Beginning with a concise presentation of the structural and functional aspects of HER2, we detail the frequency and prognostic significance of HER2 alterations in BTCs and discuss all available preclinical and clinical data on anti-HER2 agents tested for BTCs.
  • ||||||||||  MK-1084 / Merck (MSD)
    Trial completion date, Trial primary completion date, Monotherapy:  A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) -  Mar 12, 2025   
    P1,  N=830, Recruiting, 
    Beginning with a concise presentation of the structural and functional aspects of HER2, we detail the frequency and prognostic significance of HER2 alterations in BTCs and discuss all available preclinical and clinical data on anti-HER2 agents tested for BTCs. Trial completion date: Aug 2027 --> Feb 2030 | Trial primary completion date: Aug 2027 --> Feb 2030
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Review, Journal:  Adjuvant Chemotherapy in Colon Cancer: Simple is Better (Pubmed Central) -  Mar 10, 2025   
    Better patient selection is possible with the use of novel molecular-based biomarkers and circulating tumor deoxyribonucleic acid monitoring of minimal residual disease. There also needs to be special consideration for the geriatric patients-especially due to their limited mobility, comorbidities, and polypharmacy.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Gut microbiota derived DCA enhances FOLFOX efficacy via Ugt1a6b mediated enterohepatic circulation in colon cancer. (Pubmed Central) -  Mar 9, 2025   
    FOLFOX (5-Fluorouracil, Calcium Folinate combined with Oxaliplatin) is a preferred chemotherapy regimen for colon cancer, but its limited efficacy remains a major challenge, significantly impairs patient outcomes...We first demonstrated that bile acids depletion (cholestyramine treatment) enhanced FOLFOX efficacy in an orthotopic colon cancer mouse model, suggesting that bile acids play a key role in FOLFOX's therapeutic effects...Transcriptomic analysis and subsequent biological experiments revealed that DCA enhanced FOLFOX efficacy via Ugt1a6b. In conclusion, our findings establish that gut microbiota-derived DCA enhances the efficacy of FOLFOX potentially via Ugt1a6b mediated enterohepatic circulation, providing novel insights into a synergistic therapeutic strategy for improving colon cancer treatment.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2/HO1 and NF-?B Pathway. (Pubmed Central) -  Mar 7, 2025   
    In conclusion, our findings establish that gut microbiota-derived DCA enhances the efficacy of FOLFOX potentially via Ugt1a6b mediated enterohepatic circulation, providing novel insights into a synergistic therapeutic strategy for improving colon cancer treatment. Thus, our findings demonstrate that MALT1 suppression dramatically reduces FOLFOX-induced inflammatory and fibrotic conditions by modulating the NF-?B activation, paving the way for innovative HSOS therapy approaches.
  • ||||||||||  Zirabev (bevacizumab-bvzr) / Pfizer, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
    Reimbursement, US reimbursement, Journal, Medicare:  Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare. (Pubmed Central) -  Mar 4, 2025   
    The objective of this study is to explore the cost-efficiency and budget-neutral expanded access of bevacizumab-bvzr in mCRC and mNSCLC in Medicare.Methods We developed a Medicare payer perspective simulation model of patients treated for mCRC and mNSCLC to estimate cost-savings from converting bevacizumab (originator) to bevacizumab-bvzr or alternative biosimilars such as bevacizumab-awwb, -maly, and -abcd...At 100% conversion, monthly savings from biosimilar conversion could fund up to 13,887 additional mCRC patient-months of treatment with bevacizumab-bvzr?+?FOLFOX, and up to 8,959 additional mNSCLC patient-months of treatment with bevacizumab-bvzr?+?paclitaxel?+?carboplatin...The biosimilar NNC from other biosimilars ranged from 60-4,564 and 55-4,422 for mCRC and NSCLC, respectively.Conclusion In the first cost-efficiency and expanded access study of biosimilar bevacizumab in mCRC and mNSCLC, we find that bevacizumab-bvzr-based regimens can result in substantial cost savings relative to originator-based first line treatment in Medicare. These cost savings could be reinvested to treat a substantial number of additional patients with mCRC or mNSCLC, or fund other costs of care in Medicare, on a budget-neutral basis.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Biomarker, Journal:  Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients. (Pubmed Central) -  Mar 3, 2025   
    An NLR ratio less than 4 was significantly associated with longer OS (p?=?0.001). Low MBM is linked to FOLFIRINOX toxicity, suggesting MBM assessment could allow better selection of patients to avoid these toxicities, warranting further confirmation in larger cohorts.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Microglia-Mediated Synaptic Dysfunction Contributes to Chemotherapy-Related Cognitive Impairment. (Pubmed Central) -  Feb 28, 2025   
    Cotreatment with the microglial inhibitor minocycline (33?mg/kg, daily for 3?weeks) restored cognitive deficits and microglial ramification, decreased the number of CD68-positive microglia, and reversed the reductions in LTP and the amplitude of NMDAR-EPSCs in 5-Fu/LV-treated mice. Our data suggest that microglial dysfunction and related synaptic dysfunction contribute to 5-Fu/LV-induced cognitive impairment.
  • ||||||||||  Natrunix (vilamakitug) / XBiotech
    Enrollment closed, Trial completion date:  1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov) -  Feb 28, 2025   
    P1/2,  N=76, Active, not recruiting, 
    Our data suggest that microglial dysfunction and related synaptic dysfunction contribute to 5-Fu/LV-induced cognitive impairment. Completed --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Journal:  Real-life effectiveness of FLOT in resectable gastric cancer: existing challenges. (Pubmed Central) -  Feb 28, 2025   
    Nevertheless, some questions remain: the application in elderly patients, the addition of immunotherapy in patients with microsatellite instability or with high PD-L1 levels, comparison with chemoradiotherapy in junctional cancers and real cure rates. The FLOT regimen has revolutionized the treatment of resectable gastric cancer, but caution is needed before considering it an absolute standard of care.
  • ||||||||||  irinotecan / Generic mfg.
    Journal:  Irinotecan-induced dysarthria and management. (Pubmed Central) -  Feb 28, 2025   
    The FLOT regimen has revolutionized the treatment of resectable gastric cancer, but caution is needed before considering it an absolute standard of care. Prolonging the infusion and giving prophylactic atropine may help to prevent these rare adverse effects of irinotecan.
  • ||||||||||  Yidafan (ivonescimab) / Akesobio, Summit Therapeutics, ligufalimab (AK117) / Akesobio
    Enrollment change, Trial completion date, Trial primary completion date:  AK112-206: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Feb 27, 2025   
    P2,  N=254, Recruiting, 
    Not yet recruiting --> Recruiting N=104 --> 254 | Trial completion date: Dec 2026 --> Aug 2028 | Trial primary completion date: Dec 2024 --> May 2026
  • ||||||||||  Retrospective data, Review, Journal:  Associations between vascular endothelial growth factor polymorphisms and response to 5-FU-based pharmaceutical therapy in esophageal squamous cell carcinoma: A meta-analysis. (Pubmed Central) -  Feb 27, 2025   
    This literature-based meta-analysis was performed with keywords related to VEGF gene polymorphisms and clinical response in esophageal squamous carcinoma patients receiving pharmaceutical therapy (including 5-FU, cisplatin, oxaliplatin, and calcium folinate)...The presence of VEGF G-1154A and VEGF-634C/G was found to be correlated with patient response to 5-FU/CDDP-based treatment, whereas VEGF-2549I/D was correlated with response to 5-FU/oxaliplatin-based treatment, and VEGF-936C/T was associated with both 5-FU/CDDP- and 5-FU/oxaliplatin-based treatment response. VEGF gene polymorphisms affect the response of esophageal squamous carcinoma patients receiving pharmaceutical therapy, especially 5-FU-based treatments.
  • ||||||||||  Trial completion date, Trial primary completion date:  Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) -  Feb 26, 2025   
    P1,  N=20, Recruiting, 
    These findings underscore the need for further research into the molecular mechanisms of PTEN-associated pancreatic cancers and the development of targeted therapeutic strategies. Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Dec 2023 --> Jul 2026
  • ||||||||||  methotrexate / Generic mfg.
    Journal:  Dendritic Molecular Baskets for Selective Binding of Toxic Methotrexate. (Pubmed Central) -  Feb 24, 2025   
    While the host is biocompatible (HEK293; IC50 > 150 ?M) and produces inclusion complex [MTX?6]14- in cell media, it experiences limitation in pharmacokinetic sequestration of MTX2- as dihydrofolate reductase's affinity to the drug is suggested to prevail over that of 612-. Nonetheless, considering the basket's biocompatibility, tunability, and chemoselectivity, it stands as the leading candidate in the pursuit of an effective abiotic antidote for methotrexate poisoning.